All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lupus Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-05-10T11:33:52.000Z

Baricitinib in SLE: Results from the phase III SLE-BRAVE trials

May 10, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new development in lupus.

Bookmark this article

Outcomes in patients with systemic lupus erythematosus (SLE) remain poor. Conventional therapies include antimalarials, glucocorticoids, and immunosuppressants, with trials for new drugs often producing negative results and failing to progress beyond phase III trials.1

Baricitinib, an oral Janus kinase (JAK) 1 and 2 inhibitor, is already approved for several indications, including atopic dermatitis, alopecia, and rheumatoid arthritis; previous phase II trial of baricitinib have demonstrated improved SLE activity compared with placebo over 24 weeks. The SLE-BRAVE-I and -II trials (NCT03616912; NCT03616964) investigated the efficacy and safety of baricitinib in patients with SLE over 52 weeks.1,2

Trial design

SLE-BRAVE-I and SLE-BRAVE-II were both multicenter, randomized, double-blind phase III trials comparing baricitinib with placebo in patients with SLE.1,2 Eligible patients continued to receive their standard of care treatment alongside baricitinib or placebo.1,2 The study design is shown in Figure 1.

Figure 1. Trial design of SLE-BRAVE-I and SLE-BRAVE-II* 

ACR, American College of Rheumatology; BILAG, British Isles Lupus Assessment Group; CNS, central nervous system; ds, double stranded; EoT, end of treatment; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index-2000; SRI-4, SLE Responder Index-4.
*Adapted from Morand, et al.1 and Petri, et al.2

The primary endpoint for both trials was the proportion of patients achieving a SLE Responder Index (SRI)-4 response at Week 52 in the baricitinib 4 mg group compared with placebo group.1,2 Secondary endpoints included:

  • SRI-4 response at Week 24;
  • SRI-4 response at Week 52 in patients receiving baricitinib 2 mg;
  • Achievement of lupus low disease activity state at Week 52;
  • 25% decrease in prednisone dose in patients receiving 7.5 mg or more at baseline;
  • time to first severe flare;
  • change from baseline in Worst Pain Numeric Rating Scale at Week 52; and
  • change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue score at Week 52.

Adverse events were measured at each visit for both studies.

Results

In SLE-BRAVE-I, 769 patients were enrolled and 760 patients were included in the analyses.1 In SLE-BLAVE-II, 778 patients were enrolled and 775 were included in analyses.2 Key baseline patient characteristics are shown in Table 1.

Table 1. Baseline patient characteristics in SLE-BRAVE-I and -II*

Characteristic, % (unless otherwise stated)

SLE-BRAVE-I

SLE-BRAVE-II

Placebo
(n = 253)

Baricitinib 2mg
(n = 255)

Baricitinib 4mg
(n = 252)

Placebo
(n = 256)

Baricitinib 2mg
(n = 261)

Baricitinib 4mg
(n = 258)

Mean age, years

42.0

42.9

41.5

43.5

42.8

42.2

Sex

 

 

 

 

 

 

              Male

6

6

5

              Female

94

93

94

94

94

95

Race

 

 

 

 

 

 

              Asian

13

16

14

28

26

28

              Black or African
              American

14

9

12

7

9

10

              White

67

69

71

58

59

55

              Other/multiple

5

7

3

6

5

5

Mean time since onset of SLE, years

9.4

9.2

8.8

9.0

8.7

8.5

Concomitant medications

 

 

 

 

 

 

              Glucocorticoids

77

76

74

81

80

80

              Mean
              prednisone
              dose, mg/day

9.8

10.4

10.1

8.8

9.6

9.8

              Antimalarials

84

74

82

82

82

83

              Immuno-suppressants

59

60

82

55

51

52

              NSAID

25

26

27

20

25

27

Mean SLEDAI-2K score

10.1

10.3

10.0

10.1

10.1

10.1

NSAID, non-steroidal anti-inflammatory drug; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index-2000.
*Adapted from Morand, et al.1 and Petri, et al.2

Includes America Indian or Alaska Native.

Efficacy

The efficacy analysis was performed based on the intention-to-treat population.1,2 SLE-BRAVE-I did not to meet any of its major secondary endpoints,1 while SLE-BRAVE-II did not meet both its primary and major secondary endpoints.2 The proportion of patients meeting the primary outcome measures is shown in Figure 2, including the primary endpoint of SRI-4 at Week 52.

Figure 2. Primary outcomes in SLE-BRAVE-1 and SLE-BRAVE-II: A SRI-4 at Week 52, B reduction of ≥4 points from baseline in SLEDAI-2K score, C no new BILAG A and no more than one new BILAG B disease activity score, and D no worsening* 

BILAG, British Isles Lupus Assessment Group; PGA, Physician Global Assessment; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index-2000; SRI-4, SLE Responder Index-4.
*Adapted from Morand, et al.1 and Petri, et al.2
Defined as an increase of ≥0.3 points (10 mm) from baseline in PGA.

Safety

The incidence of adverse events and discontinuation was similar across treatment groups in both studies, as shown in Figure 3.1,2

Figure 3. Safety outcomes: incidence of A treatment-emergent adverse events, B serious adverse events, C infections, and D discontinuation due to adverse events*

*Adapted from Morand, et al.1 and Petri, et al.2

Two deaths due to COVID-19 were reported in SLE-BRAVE-I, one in a patient receiving placebo and one receiving baricitinib 2 mg.1 In SLE-BRAVE-II, four deaths were reported in patients treated with baricitinib 4 mg, two due to myocardial infarction, one due to COVID-19 (this patient was meant to receive baricitinib 4 mg but actually received baricitinib 2 mg), and one due to sepsis; there were three deaths in placebo treated patients, all due to respiratory failure.2

Conclusion 

Despite positive results in a phase II trial in patients with SLE, baricitinib failed to meet the major secondary endpoints in both trials, with the primary endpoint not being met in SLE-BRAVE-II.1,2 However, there were no new safety signals observed in either trial.1,2

SLE-BRAVE-X, a phase III long-term extension in adults who completed SLE-BRAVE-II and -II, evaluated the safety and efficacy of baricitinib over three years; however, development of baricitinib for SLE has now been discontinued due to the poor efficacy outcomes seen in SLE-BRAVE-I and -II.3

  1. Morand E, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401(10381):1001-1010. DOI:1016/S0140-6736(22)02607-1
  2. Petri M, Bruce IN, Dörner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023;401(10381):1011-1019. DOI:1016/S0140-6736(22)02546-6
  3. Lilly.  Updates on OLUMIANT® (baricitinib) phase 3 lupus program and FDA review for atopic dermatitis. https://investor.lilly.com/news-releases/news-release-details/updates-olumiantr-baricitinib-phase-3-lupus-program-and-fda. Published Jan 28, 2022. Accessed Apr 21, 2023.

Newsletter

Subscribe to get the best content related to lupus delivered to your inbox